Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

Gout is a disease characterized by recurrent attacks of arthritis, in which uric acid appears in excessive amounts in the ...

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

According to the NHS the main symptoms of gout are sudden severe pain in a joint – usually your big toe, but it can be in ...

Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.

The relationship between food allergies and chronic illness represents one of the most significant yet underappreciated ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Strategic anti-inflammatory food choices target underlying inflammatory pathways to reduce chronic pain intensity and ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

[PubMed: 18710901] (9) Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther.

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

There are numerous risk factors which boost your chances of having it, including being overweight, smoking, joint injuries, ...